300110 华仁药业
交易中 06-05 10:03:30
资讯
新帖
简况
股市必读：华仁药业(300110)股东户数3.83万户，较上期减少1.79%
证券之星 · 06-01
股市必读：华仁药业(300110)股东户数3.83万户，较上期减少1.79%
华仁药业(300110)5月20日股东户数3.83万户，较上期减少1.79%
证券之星 · 05-29
华仁药业(300110)5月20日股东户数3.83万户，较上期减少1.79%
华仁药业（300110）披露为子公司提供担保进展公告，5月25日股价上涨0.69%
证券之星 · 05-25
华仁药业（300110）披露为子公司提供担保进展公告，5月25日股价上涨0.69%
华仁药业(300110)5月8日股东户数3.9万户，较上期减少0.26%
证券之星 · 05-21
华仁药业(300110)5月8日股东户数3.9万户，较上期减少0.26%
华仁药业：公司高管调整均为结合战略布局、经营管理及人才建设的正常人事安排
证券之星 · 05-21
华仁药业：公司高管调整均为结合战略布局、经营管理及人才建设的正常人事安排
华仁药业：公司严格按照企业会计准则审慎开展资产减值计提
证券之星 · 05-21
华仁药业：公司严格按照企业会计准则审慎开展资产减值计提
华仁药业（300110）披露2025年度股东会决议公告，5月18日股价下跌0.67%
证券之星 · 05-18
华仁药业（300110）披露2025年度股东会决议公告，5月18日股价下跌0.67%
每周股票复盘：华仁药业（300110）股东户数较上期减少200户
证券之星 · 05-03
每周股票复盘：华仁药业（300110）股东户数较上期减少200户
华仁药业：相关事项调整尚处于规划阶段
证券之星 · 04-29
华仁药业：相关事项调整尚处于规划阶段
股市必读：华仁药业(300110)股东户数3.92万户，较上期减少0.51%
证券之星 · 04-29
股市必读：华仁药业(300110)股东户数3.92万户，较上期减少0.51%
华仁药业：核心聚焦公司整体发展战略、业务布局、经营思路与发展路径
证券之星 · 04-28
华仁药业：核心聚焦公司整体发展战略、业务布局、经营思路与发展路径
股市必读：华仁药业年报 - 第四季度单季净利润同比增长64.65%
证券之星 · 04-27
股市必读：华仁药业年报 - 第四季度单季净利润同比增长64.65%
华仁药业（300110）2026年一季报简析：增收不增利
证券之星 · 04-25
华仁药业（300110）2026年一季报简析：增收不增利
图解华仁药业年报：第四季度单季净利润同比增长64.65%
证券之星 · 04-24
图解华仁药业年报：第四季度单季净利润同比增长64.65%
华仁药业：截至2026年4月10日，公司股东总户数约为3.94万户
证券之星 · 04-13
华仁药业：截至2026年4月10日，公司股东总户数约为3.94万户
华仁药业最新公告：乳酸钠林格注射液取得药品补充申请批准通知书
证券之星 · 04-08
华仁药业最新公告：乳酸钠林格注射液取得药品补充申请批准通知书
华仁药业最新公告：乳酸钠林格注射液通过仿制药一致性评价
证券之星 · 03-25
华仁药业最新公告：乳酸钠林格注射液通过仿制药一致性评价
华仁药业：截至2026年3月20日，公司股东总户数约为3.86万户
证券之星 · 03-24
华仁药业：截至2026年3月20日，公司股东总户数约为3.86万户
国药药材品牌授权乱象
中国经营网 · 03-21
国药药材品牌授权乱象
华仁药业：二级市场股价波动受多方面因素影响
证券之星 · 03-17
华仁药业：二级市场股价波动受多方面因素影响
加载更多
公司概况
公司名称：
华仁药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-08-25
主营业务：
华仁药业股份有限公司的主营业务是原料药、制剂、医疗器械、医用包材、大健康产品的研发、生产、销售。公司的主要产品是基础输液、治疗制剂、腹透液。公司先后获得“全国AAA级信用企业”、“中国化学制药行业工业企业综合实力百强”、“中国医药工业百强”等荣誉。
发行价格：
13.99
{"stockData":{"symbol":"300110","market":"SZ","secType":"STK","nameCN":"华仁药业","latestPrice":2.78,"timestamp":1780625010000,"preClose":2.75,"halted":0,"volume":6085880,"delay":0,"changeRate":0.0109,"floatShares":1181000000,"shares":1182000000,"eps":-0.3917,"marketStatus":"交易中","change":0.03,"latestTime":"06-05 10:03:30","open":2.76,"high":2.82,"low":2.76,"amount":16965000,"amplitude":0.0218,"askPrice":2.78,"askSize":1113,"bidPrice":2.77,"bidSize":4180,"shortable":0,"etf":0,"ttmEps":-0.3917,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1780630200000},"marketStatusCode":2,"adr":0,"adjPreClose":2.75,"symbolType":"stock","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":3.03,"lowLimit":2.48,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1182212982,"isCdr":false,"pbRate":3.81,"roa":"--","roe":"1.89%","epsLYR":-0.3916,"committee":0.204346,"marketValue":3287000000,"turnoverRate":0.0052,"status":0,"floatMarketCap":3284000000},"requestUrl":"/m/hq/s/300110","defaultTab":"news","newsList":[{"id":"2640089985","title":"股市必读：华仁药业(300110)股东户数3.83万户，较上期减少1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640089985","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640089985?lang=zh_cn&edition=full","pubTime":"2026-06-01 04:26","pubTimestamp":1780259172,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，华仁药业报收于2.8元，上涨0.0%，换手率1.38%，成交量16.31万手，成交额4580.01万元。来自股本股东变化：截至5月20日股东户数环比下降1.79%，筹码集中度有所提升。股本股东变化股东户数变动近日华仁药业披露，截至2026年5月20日公司股东户数为3.83万户，较5月8日减少700.0户，减幅为1.79%。户均持股数量由上期的3.03万股增加至3.09万股，户均持股市值为9.07万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639626542","title":"华仁药业(300110)5月20日股东户数3.83万户，较上期减少1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639626542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639626542?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:52","pubTimestamp":1780048348,"startTime":"0","endTime":"0","summary":"证券之星消息，近日华仁药业披露，截至2026年5月20日公司股东户数为3.83万户，较5月8日减少700.0户，减幅为1.79%。在化学制药行业个股中，华仁药业股东户数高于行业平均水平，截至5月20日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年5月8日至2026年5月20日，华仁药业区间跌幅为4.85%，在此期间股东户数减少700.0户，减幅为1.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900033407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638556902","title":"华仁药业（300110）披露为子公司提供担保进展公告，5月25日股价上涨0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638556902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638556902?lang=zh_cn&edition=full","pubTime":"2026-05-25 23:00","pubTimestamp":1779721244,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，华仁药业报收于2.92元，较前一交易日上涨0.69%，最新总市值为34.52亿元。华仁药业股份有限公司于2026年5月25日发布公告，公司与合肥科技农村商业银行股份有限公司包河支行签订《保证合同》，为全资子公司安徽恒星制药有限公司提供1,000万元连带责任保证担保。截至公告日，公司对子公司实际担保总余额为43,887万元，占最近一期经审计净资产的52.38%，无逾期担保及其他风险情形。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500034459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637838132","title":"华仁药业(300110)5月8日股东户数3.9万户，较上期减少0.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637838132","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637838132?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:43","pubTimestamp":1779356605,"startTime":"0","endTime":"0","summary":"证券之星消息，近日华仁药业披露，截至2026年5月8日公司股东户数为3.9万户，较4月30日减少100.0户，减幅为0.26%。在化学制药行业个股中，华仁药业股东户数高于行业平均水平，截至5月8日，化学制药行业平均股东户数为3.57万户。从股价来看，2026年4月30日至2026年5月8日，华仁药业区间跌幅为1.9%，在此期间股东户数减少100.0户，减幅为0.26%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100032759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637872762","title":"华仁药业：公司高管调整均为结合战略布局、经营管理及人才建设的正常人事安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2637872762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637872762?lang=zh_cn&edition=full","pubTime":"2026-05-21 08:48","pubTimestamp":1779324491,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：频繁的更换高管这样是否有助于公司发展？华仁药业回复：您好，公司高管调整均为结合战略布局、经营管理及人才建设的正常人事安排，严格履行法定决策程序。公司始终坚持选优配强核心管理团队，持续优化人才梯队建设，凝聚专业管理力量，夯实经营发展根基，推动公司高质量可持续发展。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100009093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0102","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637727138","title":"华仁药业：公司严格按照企业会计准则审慎开展资产减值计提","url":"https://stock-news.laohu8.com/highlight/detail?id=2637727138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637727138?lang=zh_cn&edition=full","pubTime":"2026-05-21 08:48","pubTimestamp":1779324491,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：公司管理不善造成债务无法收回商誉高起，这种情况下的财务计提为什么要有股东承担损失后果？华仁药业回复：您好，公司严格按照企业会计准则审慎开展资产减值计提，真实反映经营实际。公司将持续强化资产管理与风险防控，以稳健经营维护全体股东长期利益。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100009095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300110","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636022842","title":"华仁药业（300110）披露2025年度股东会决议公告，5月18日股价下跌0.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636022842","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636022842?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:27","pubTimestamp":1779100035,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，华仁药业报收于2.97元，较前一交易日下跌0.67%，最新总市值为35.11亿元。该股当日开盘2.98元，最高2.98元，最低2.93元，成交额达4311.42万元，换手率为1.24%。华仁药业于近日披露《2025年度股东会决议公告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800029539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632677102","title":"每周股票复盘：华仁药业（300110）股东户数较上期减少200户","url":"https://stock-news.laohu8.com/highlight/detail?id=2632677102","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632677102?lang=zh_cn&edition=full","pubTime":"2026-05-03 05:55","pubTimestamp":1777758915,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，华仁药业报收于3.15元，较上周的3.09元上涨1.94%。本周，华仁药业4月30日盘中最高价报3.2元。4月27日盘中最低价报2.99元。华仁药业当前最新总市值37.24亿元，在化学制药板块市值排名118/150，在两市A股市值排名4164/5200。户均持股数量由上期的3.0万股上升至3.02万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300110","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631514623","title":"华仁药业：相关事项调整尚处于规划阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2631514623","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631514623?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:53","pubTimestamp":1777467192,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问公司的控股股东曲江文投虽然曲江新区管委会的撤销，会对公司有说明样的影响，后续还会有资产注入到公司吗？华仁药业回复：尊敬的投资者您好，目前相关事项调整尚处于规划阶段，相关落地实施存在不确定性且需要一定时间推进。未来如有资产注入等资本运作相关计划，公司将严格按照法律法规及监管要求，及时履行信息披露义务，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900062868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631537490","title":"股市必读：华仁药业(300110)股东户数3.92万户，较上期减少0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631537490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631537490?lang=zh_cn&edition=full","pubTime":"2026-04-29 07:12","pubTimestamp":1777417933,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘，华仁药业报收于3.08元，下跌0.65%，换手率2.24%，成交量26.49万手，成交额8186.5万元。来自股本股东变化：截至4月20日股东户数环比下降0.51%，筹码集中度有所提升。股本股东变化股东户数变动近日华仁药业披露，截至2026年4月20日公司股东户数为3.92万户，较4月10日减少200.0户，减幅为0.51%。户均持股数量由上期的3.0万股增加至3.02万股，户均持股市值为9.41万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900019118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0239","300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630302915","title":"华仁药业：核心聚焦公司整体发展战略、业务布局、经营思路与发展路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2630302915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630302915?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:48","pubTimestamp":1777380490,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业04月27日在投资者关系平台上答复投资者关心的问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800060747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300110","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630649339","title":"股市必读：华仁药业年报 - 第四季度单季净利润同比增长64.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630649339","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630649339?lang=zh_cn&edition=full","pubTime":"2026-04-27 04:41","pubTimestamp":1777236070,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，华仁药业报收于3.09元，上涨1.31%，换手率2.12%，成交量25.05万手，成交额7692.7万元。股本股东变化股东户数变动近日华仁药业披露，截至2026年4月10日公司股东户数为3.94万户，较3月31日增加582.0户，增幅为1.5%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630873384","title":"华仁药业（300110）2026年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2630873384","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630873384?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:27","pubTimestamp":1777069624,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期华仁药业发布2026年一季报。根据财报显示，华仁药业增收不增利。截至本报告期末，公司营业总收入3.1亿元，同比上升2.14%，归母净利润1595.86万元，同比下降0.44%。本次财报公布的各项数据指标表现一般。从历史年报数据统计来看，公司近10年来中位数ROIC为2.93%，中位投资回报较弱，其中最惨年份2024年的ROIC为-34.45%，投资回报极差。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500020801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300110","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629854123","title":"图解华仁药业年报：第四季度单季净利润同比增长64.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629854123","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629854123?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:55","pubTimestamp":1776966920,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业2025年年报显示，当年度公司主营收入13.21亿元，同比下降2.34%；归母净利润-4.63亿元，同比上升66.17%；扣非净利润-4.7亿元，同比上升65.88%；其中2025年第四季度，公司单季度主营收入3.45亿元，同比上升23.48%；单季度归母净利润-5.17亿元，同比上升64.65%；单季度扣非净利润-5.16亿元，同比上升64.85%；负债率66.36%，投资收益481.58万元，财务费用4229.97万元，毛利率37.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400004742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627453117","title":"华仁药业：截至2026年4月10日，公司股东总户数约为3.94万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2627453117","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627453117?lang=zh_cn&edition=full","pubTime":"2026-04-13 20:48","pubTimestamp":1776084493,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)04月13日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好！请问一下截止到2026.04.10的股东数是多少？谢谢啊！！！华仁药业回复：尊敬的投资者您好，截至2026年4月10日，公司股东总户数约为3.94万户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300031587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625917288","title":"华仁药业最新公告：乳酸钠林格注射液取得药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2625917288","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625917288?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:53","pubTimestamp":1775642019,"startTime":"0","endTime":"0","summary":"华仁药业(300110.SZ)公告称，公司近日收到国家药监局核准签发的乳酸钠林格注射液(规格：1000ml)《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价，并同意变更药品生产工艺。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800028166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0102","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622202965","title":"华仁药业最新公告：乳酸钠林格注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2622202965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622202965?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:11","pubTimestamp":1774429894,"startTime":"0","endTime":"0","summary":"华仁药业公告称，公司近日收到国家药监局核准签发的乳酸钠林格注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。乳酸钠林格注射液是一种调节体液、电解质及酸碱平衡药，适用于代谢性酸中毒或有代谢性酸中毒的脱水患者。公司表示，此次通过一致性评价有助于提升产品市场竞争力，但未来销售受集采、政策及市场环境等因素影响，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500031859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300110","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067986","title":"华仁药业：截至2026年3月20日，公司股东总户数约为3.86万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621067986?lang=zh_cn&edition=full","pubTime":"2026-03-24 20:52","pubTimestamp":1774356760,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)03月23日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘 你好 衷心感谢你们不厌其烦回答投资者的提问。请问贵公司2026年3月20日A股股东人数是多少？谢谢华仁药业回复：尊敬的投资者您好，截至2026年3月20日，公司股东总户数约为3.86万户。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400037729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300110","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621757877","title":"国药药材品牌授权乱象","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757877","media":"中国经营网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621757877?lang=zh_cn&edition=full","pubTime":"2026-03-21 04:10","pubTimestamp":1774037429,"startTime":"0","endTime":"0","summary":"“央企品质特供”“中国新中式滋补行业第一央企”“世界500强第80位”……近日，《中国经营报》记者注意到，在多个电商平台，有许多标注“国药药材”品牌的中药保健品、饮片在大量销售，这些商品甚至直接使用国药集团权威背景信息。国药药材全称为国药药材股份有限公司，曾因拖欠上市公司华仁药业（300110.SZ）14亿元以及多次被国药集团打假而在业内“闻名”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603213679341730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0102","BK0239","BK1606","BK1191","BK1515","300110","00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620275844","title":"华仁药业：二级市场股价波动受多方面因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620275844?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:53","pubTimestamp":1773751981,"startTime":"0","endTime":"0","summary":"证券之星消息，华仁药业(300110)03月17日在投资者关系平台上答复投资者关心的问题。投资者提问：腹膜透析作为国内前列的治疗药物！为什么股价在市场上表现的默默无闻！华仁药业回复：尊敬的投资者您好，二级市场股价波动受多方面因素影响。公司管理层始终以公司长远发展和股东利益为重，未来将继续努力提升公司经营质量，加速实施提升盈利能力的各项举措，努力提升上市公司投资价值，增强投资者回报水平。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300110","BK0239","BK0102"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780625013158,"stockEarnings":[{"period":"1week","weight":-0.0179},{"period":"1month","weight":-0.127},{"period":"3month","weight":-0.159},{"period":"6month","weight":-0.221},{"period":"1year","weight":-0.1564},{"period":"ytd","weight":-0.127}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.0161},{"period":"6month","weight":0.0397},{"period":"1year","weight":0.2019},{"period":"ytd","weight":0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华仁药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38400人(较上一季度增加0.26%)","perCapita":"30759股","listingDate":"2010-08-25","address":"山东省青岛市崂山区高科技工业园株洲路187号","registeredCapital":"118221万元","survey":" 华仁药业股份有限公司的主营业务是原料药、制剂、医疗器械、医用包材、大健康产品的研发、生产、销售。公司的主要产品是基础输液、治疗制剂、腹透液。公司先后获得“全国AAA级信用企业”、“中国化学制药行业工业企业综合实力百强”、“中国医药工业百强”等荣誉。","listedPrice":13.99},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华仁药业(300110)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华仁药业(300110)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华仁药业,300110,华仁药业股票,华仁药业股票老虎,华仁药业股票老虎国际,华仁药业行情,华仁药业股票行情,华仁药业股价,华仁药业股市,华仁药业股票价格,华仁药业股票交易,华仁药业股票购买,华仁药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华仁药业(300110)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华仁药业(300110)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}